製品番号: HY-17504A

Rosuvastatin

(別名: ZD 4522; ロスバスタチンカルシウム)

27 Cited Publications

カスタマーレビュー

Based on 27 publication(s) in Google Scholar

Rosuvastatin (ZD 4522) is a competitive HMG-CoA reductase inhibitor with an IC₅₀ of 11 nM. Rosuvastatin potently blocks hERG current with an IC₅₀ of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction of heat shock protein 70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL) cholesterol, triglycerides, and C-reactive protein levels.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.67%
CAS 番号: 287714-41-4
分子式: C₂₂H₂₈FN₃O₆S
分子量:481.54

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Rosuvastatin 構造式

CAS 番号: 287714-41-4

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体内実験
化学情報
Publications (27)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

IC₅₀ & Target

IC50: 11 nM (HMG-CoA), 195 nM (hERG)^[1]^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
Hepatocyte	IC₅₀	0.23 nM Compound: ros, rosuvastatin	Inhibition of cholesterol synthesis in rat liver hepatocytes after 4 hrs Inhibition of cholesterol synthesis in rat liver hepatocytes after 4 hrs	[PMID: 17560788]
Hepatocyte	IC₅₀	0.23 nM Compound: 1, rosuvastatin	Inhibition of cholesterol synthesis in rat hepatocytes Inhibition of cholesterol synthesis in rat hepatocytes	[PMID: 17764936]
Hepatocyte	IC₅₀	0.23 nM Compound: 26	Inhibition of cholesterol synthesis in rat hepatocytes Inhibition of cholesterol synthesis in rat hepatocytes	[PMID: 18540668]
Hepatocyte	IC₅₀	0.27 nM Compound: Rosuvastatin	Inhibition of cholesterol synthesis in rat hepatocyte Inhibition of cholesterol synthesis in rat hepatocyte	[PMID: 17574412]
Hepatocyte	IC₅₀	0.27 nM Compound: rosuvastatin	Inhibition of cholesterol synthesis in rat hepatocyte Inhibition of cholesterol synthesis in rat hepatocyte	[PMID: 18155906]
Hepatocyte	IC₅₀	0.3 nM Compound: Rosuvastatin	Inhibition of cholesterol synthesis in rat hepatocytes assessed as reduction of [14C]-cholesterol level using [14C]-acetic acid preincubated for 4 hrs before addition of [14C]-acetic acid by liquid scintillation counting Inhibition of cholesterol synthesis in rat hepatocytes assessed as reduction of [14C]-cholesterol level using [14C]-acetic acid preincubated for 4 hrs before addition of [14C]-acetic acid by liquid scintillation counting	[PMID: 21183342]
Hepatocyte	IC₅₀	0.3 nM Compound: rosuvastatin	Inhibition of cholesterol synthesis in rat hepatocytes Inhibition of cholesterol synthesis in rat hepatocytes	[PMID: 18072721]
Hepatocyte	IC₅₀	0.6 nM Compound: rosuvastatin	Inhibition of cholesterol synthesis in rat hepatocytes assessed as incorporation of [14C]acetate into cholesterol Inhibition of cholesterol synthesis in rat hepatocytes assessed as incorporation of [14C]acetate into cholesterol	[PMID: 18412317]
L6	IC₅₀	210 nM Compound: 1, rosuvastatin	Inhibition of cholesterol synthesis in L6 myocytes Inhibition of cholesterol synthesis in L6 myocytes	[PMID: 17764936]
L6	IC₅₀	250 nM Compound: Rosuvastatin	Inhibition of cholesterol synthesis in rat L6 cells assessed as reduction of [14C]-cholesterol level using [14C]-acetic acid preincubated for 3 hrs before addition of [14C]-acetic acid by scintillation counting Inhibition of cholesterol synthesis in rat L6 cells assessed as reduction of [14C]-cholesterol level using [14C]-acetic acid preincubated for 3 hrs before addition of [14C]-acetic acid by scintillation counting	[PMID: 21183342]
L6	IC₅₀	250 nM Compound: rosuvastatin	Inhibition of cholesterol synthesis in rat L6 cells Inhibition of cholesterol synthesis in rat L6 cells	[PMID: 18072721]
L6	IC₅₀	250 nM Compound: rosuvastatin	Inhibition of cholesterol synthesis in rat L6 myocyte Inhibition of cholesterol synthesis in rat L6 myocyte	[PMID: 18155906]
L6	IC₅₀	65 nM Compound: rosuvastatin	Inhibition of cholesterol synthesis in rat L6 cells assessed as incorporation of [14C]acetate into cholesterol Inhibition of cholesterol synthesis in rat L6 cells assessed as incorporation of [14C]acetate into cholesterol	[PMID: 18412317]
L6	IC₅₀	720 nM Compound: ros, rosuvastatin	Inhibition of cholesterol synthesis in rat L6 cells after 3 hrs Inhibition of cholesterol synthesis in rat L6 cells after 3 hrs	[PMID: 17560788]
L6	IC₅₀	720 nM Compound: 26	Inhibition of cholesterol synthesis in rat L6 myocytes Inhibition of cholesterol synthesis in rat L6 myocytes	[PMID: 18540668]
Ventricular myocyte	IC₅₀	250 nM Compound: Rosuvastatin	Inhibition of cholesterol synthesis in rat myocyte Inhibition of cholesterol synthesis in rat myocyte	[PMID: 17574412]

体内実験

Rosuvastatin (10 mg/kg, intraperitoneal) prolonges QTc in conscious and unrestraines guinea pigs from 201±1 to 210±2 ms^[2].
Rosuvastatin (20 mg/kg/day, for 2 weeks) significantly reduces very low-density lipoproteins (VLDL) in diabetes mellitus rats induced by Streptozocin^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

化学情報

CAS 番号 287714-41-4
性状 Solid
分子量 481.54
分子式 C₂₂H₂₈FN₃O₆S
Color White to off-white
SMILES

O=C(O)C[C@H](O)C[C@H](O)/C=C/C1=C(C(C)C)N=C(N(C)S(=O)(C)=O)N=C1C2=CC=C(F)C=C2
別名

ZD 4522; ロスバスタチンカルシウム
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (27)

All WBBio/Physico-chemical AssayIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Cell Metab

Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. [Abstract]

2025 Sep 2;37(9):1907-1925.e14. PMID: 40803319
MedComm (2020)

Statins, but not proprotein convertase subtilisin-kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low-density lipoprotein receptor upregulation. [Abstract]

2024 Aug 31;5(9):e681. PMID: 39220103

Rosuvastatin purchased from MedChemExpress. Usage Cited in: MedComm (2020). 2024 Aug 31;5(9):e681. [Abstract]

Chemerin levels in the medium of HepG2 cells cultured for 48 h, in the absence (control) or presence of atorvastatin, evolocumab, or Rosuvastatin, were measured.
Adv Sci (Weinh)

Short-Term Statin Therapy Induces Hepatic Insulin Resistance Through HNF4α/PAQR9/PPM1α Axis Regulated AKT Phosphorylation. [Abstract]

2024 Jul 5:e2403451. PMID: 38970167

Rosuvastatin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jul 5:e2403451. [Abstract]

Western blotting of PAQR9 in mouse primary hepatocytes under the treatment of DMSO, simvastatin (Sim), atorvastatin (Ator), and rosuvastatin (Rosu) (10 μM; 24–48 h) was performed.
Biosens Bioelectron

Drug functionalized organic electromechanical transistor for rapid and sensitive detection of C-reactive protein. [Abstract]

2025 Nov 15:288:117807. PMID: 40712486
Phytomedicine

Theaflavin-3,3'-digallate stabilizes vulnerable plaques by reprogramming metabolic homeostasis in neovascularization via HK2/TIGAR. [Abstract]

2025 Jun 19:145:157014. PMID: 40570559
Phytomedicine

Gut microbiome and metabolomic profiles reveal the antiatherosclerotic effect of indole-3-carbinol in high-choline-fed ApoE-/- mice. [Abstract]

2024 Jul:129:155621. PMID: 38678950
Cell Death Discov

Upregulation of rate-limiting enzymes in cholesterol metabolism by PKCδ mediates endothelial apoptosis in diabetic wound healing. [Abstract]

2024 May 29;10(1):263. PMID: 38811564

Rosuvastatin purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 May 29;10(1):263. [Abstract]

Rosuvastatin calcium (5 mg/kg i.p.) was administered. Images of the wound area in the rosuvastatin calcium-treated group and the control group were captured.

Rosuvastatin purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2024 May 29;10(1):263. [Abstract]

Rosuvastatin calcium (5 mg/kg i.p.) was administered. The free cholesterol level of skin tissue after rosuvastatin calcium treatment for 12 days was measured. Each experiment was replicated at least thrice and representative images were shown.
Acta Pharmacol Sin

Bavachin protects against diet-induced hepatic steatosis and obesity in mice. [Abstract]

2023 Jul;44(7):1416-1428. PMID: 36721007

Rosuvastatin purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 Jul;44(7):1416-1428. [Abstract]

Rosuvastatin calcium (10 mg/kg body weight every second day, n = 5) was administered. The body weights of control and bavachin-treated mice were measured weekly from weeks 1 to 20.
Free Radic Biol Med

Rosuvastatin ameliorates high-altitude cerebral edema by promoting blood-brain barrier integrity via the regulation of energy metabolism. [Abstract]

2026 Jun 24:254:360-369. PMID: 42341957
Front Bioeng Biotechnol

Application of 3D Hepatic Plate-Like Liver Model for Statin-Induced Hepatotoxicity Evaluation. [Abstract]

2022 Mar 17;10:826093. PMID: 35372314
Eur J Pharmacol

Combining idebenone and rosuvastatin prevents atherosclerosis by suppressing oxidative stress and NLRP3 inflammasome activation. [Abstract]

2023 Sep 15:955:175911. PMID: 37451421
Front Cell Dev Biol

Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis. [Abstract]

2022 Mar 3;10:806081. PMID: 35309902
Front Cell Dev Biol

Pyk2/MCU Pathway as a New Target for Reversing Atherosclerosis. [Abstract]

2021 May 6;9:651579. PMID: 34026753
ACS Omega

Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]

2025 Oct 29;10(44):52562-52575. PMID: 41244417
Cell Signal

Rosuvastatin inhibits carcinogenesis through Ca2+ triggered endoplasmic reticulum stress pathway in pancreatic cancer. [Abstract]

2025 Jul:131:111753. PMID: 40107481
J Inflamm Res

Rosuvastatin Enhances Alveolar Fluid Clearance in Lipopolysaccharide-Induced Acute Lung Injury by Activating the Expression of Sodium Channel and Na,K-ATPase via the PI3K/AKT/Nedd4-2 Pathway. [Abstract]

2021 Apr 16:14:1537-1549. PMID: 33889010
FASEB J

Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in Cisplatin-Resistant Cervical Cancer Cells. [Abstract]

2026 May 15;40(9):e71873. PMID: 42087353
Pharm Res

Profiling Interactions Between Bicyclol and SLC/ABC Transporters: Advancing Clinical Safety and Efficacy in Combination Therapy. [Abstract]

2025 Oct 27. PMID: 41145746
Front Oncol

Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor. [Abstract]

2021 May 10:11:595285. PMID: 34041015
PLoS One

Rosuvastatin protects against oxLDL-induced endothelial cell oxidative stress and attenuates atherosclerotic plaque formation in ApoE-/- mice through the NF-κB pathway. [Abstract]

2026 Feb 20;21(2):e0339967. PMID: 41719299
Exp Ther Med

Rosuvastatin protects PC12 cells from hypoxia/reoxygenation-induced injury by inhibiting endoplasmic reticulum stress-induced apoptosis. [Abstract]

2021 Oct;22(4):1189. PMID: 34475979
bioRxiv

2026 May 25.
Vasc Endovasc Rev

2025 Nov 7.
Biomed Pharmacother

Integrated pharmacokinetic properties and tissue distribution of Corydalis saxicola Bunting total alkaloids in HFHCD-induced mice: Implications for pharmacokinetic variability in MASH treatment. [Abstract]

2025 Oct 21:192:118665. PMID: 41124864
J Nephropharmacol

2025 Sep 20:e12798
World J Methodol

Anticonvulsant potential of rosuvastatin in combination with carbamazepine and valproate in animal models of epilepsy. [Abstract]

2025 Jun 20;15(2):99580. PMID: 40548212
bioRxiv

2024 November 08.

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (207.67 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0767 mL

10.3834 mL

20.7667 mL

5 mM

0.4153 mL

2.0767 mL

4.1533 mL

10 mM

0.2077 mL

1.0383 mL

2.0767 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.19 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (276 KB)
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Watanabe, M., et al., Synthesis and biological activity of methanesulfonamide pyrimidine- and N-methanesulfonyl pyrrole-substituted 3,5-dihydroxy-6-heptenoates, a novel series of HMG-CoA reductase inhibitors. Bioorg Med Chem, 1997. 5(2): p. 437-44. [Content Brief]

[2]. Plante I, et al. Rosuvastatin blocks hERG current and prolongs cardiac repolarization. J Pharm Sci. 2012 Feb;101(2):868-78. [Content Brief]

[3]. Feng PF, et al. Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane. Mol Pharm. 2019 Apr 1;16(4):1477-1488. [Content Brief]

[4]. Carswell C.I., et al. Rosuvastatin. Drugs, 2002. 62(14): p. 2075-85; discussion 2086-7. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0767 mL	10.3834 mL	20.7667 mL	51.9168 mL
	5 mM	0.4153 mL	2.0767 mL	4.1533 mL	10.3834 mL
	10 mM	0.2077 mL	1.0383 mL	2.0767 mL	5.1917 mL
	15 mM	0.1384 mL	0.6922 mL	1.3844 mL	3.4611 mL
	20 mM	0.1038 mL	0.5192 mL	1.0383 mL	2.5958 mL
	25 mM	0.0831 mL	0.4153 mL	0.8307 mL	2.0767 mL
	30 mM	0.0692 mL	0.3461 mL	0.6922 mL	1.7306 mL
	40 mM	0.0519 mL	0.2596 mL	0.5192 mL	1.2979 mL
	50 mM	0.0415 mL	0.2077 mL	0.4153 mL	1.0383 mL
	60 mM	0.0346 mL	0.1731 mL	0.3461 mL	0.8653 mL
	80 mM	0.0260 mL	0.1298 mL	0.2596 mL	0.6490 mL
	100 mM	0.0208 mL	0.1038 mL	0.2077 mL	0.5192 mL

Rosuvastatin

27 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Rosuvastatin

Anti-Infection Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Autophagy Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Anti-Cardiovascular Disease Compound Library

Antibacterial Compound Library

Ferroptosis Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Alzheimer's Disease Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Lipid Metabolism Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Potassium Channel Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cell Death Library

Ion Channel Compound Library

Extracellular Vesicles (EVs) Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

RNA Binding Bioactive Compound Library

Classic FDA-Approved Drug Library

MedChemExpress（MCE）の使用を引用している文献 Rosuvastatin

生物活性

化学情報

Publications (27)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Rosuvastatin 関連分類

HY-17504A 関連分類